Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A Case Series Of Continuous Low Dose Lenalidomide In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

Ahmed Sawas, MD, Sean Clark-Garvey, MPH, Ellen Neylon, FNP, MSN, RN, OCN, Ameet Narwal, MPH, Kathleen Maignan, FNP, Emily Lichtenstein, RN, Owen A. O'Connor, MD, PhD

Blood (2013) 122 (21): 5134.

https://doi.org/10.1182/blood.V122.21.5134.5134

Published: 2013

Journal Articles

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Jennifer E. Amengual, Sean Clark-Garvey, Matko Kalac, Luigi Scotto, Enrica Marchi, Ellen Neylon, Paul Johannet, Ying Wei, Jasmine Zain, Owen A. O’Connor

Blood (2013) 122 (12): 2104–2113.

https://doi.org/10.1182/blood-2013-02-485441

Published: 2013

Journal Articles

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

Jennifer E Amengual, MD, Sean Clark-Garvey, Matko Kalac, MD, PhD, Luigi Scotto, PhD, Enrica Marchi, MD, PhD, Celests Rojas, Ellen Neylon, FNP, MSN, RN, OCN, Paul M Johannet, Salvia Jain, MD, Jasmine M. Zain, MD, Owen A. O'Connor, MD, PhD

Blood (2012) 120 (21): 2725.

https://doi.org/10.1182/blood.V120.21.2725.2725

Published: 2012

Journal Articles

PD-1 Is Elevated on the Peripheral Blood T Cell Subsets of Patients with Relapsed/Refractory Hodgkin Lymphoma Compared to Normal Volunteers

Catherine S. Diefenbach, MD, Rachel Sabado, PhD, Sean Clark-Garvey, Crystal Cruz, Isabelita Vengco, Celeste N Rojas, Victoria Serrano, MPH, Jasmine M. Zain, MD, Hearn J. Cho, MD, PhD, Owen A. O'Connor, MD, PhD

Blood (2011) 118 (21): 4860.

https://doi.org/10.1182/blood.V118.21.4860.4860

Published: 2011

Journal Articles

Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series

Francesca Montanari, MD, Govind Bhagat, MD, Venkatraman Seshan, Sean Clark-Garvey, Jasmine M. Zain, MD, Catherine S. Diefenbach, MD, Erin McCormick, Meaghan Conroy, Meghan Crook, Bachir Alobeid, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 4151.

https://doi.org/10.1182/blood.V116.21.4151.4151

Published: 2010

NARROW

A Case Series Of Continuous Low Dose Lenalidomide In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

PD-1 Is Elevated on the Peripheral Blood T Cell Subsets of Patients with Relapsed/Refractory Hodgkin Lymphoma Compared to Normal Volunteers

Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series

Email alerts

ASH Publications

American Society of Hematology

A Case Series Of Continuous Low Dose Lenalidomide In Patients With Relapsed Or Refractory Classical Hodgkin Lymphoma

Sirtuin and pan-class I/II deacetylase (DAC) inhibition is synergistic in preclinical models and clinical studies of lymphoma

Sirtuin Inhibition in Combination with Histone Deacetylase (HDAC) Inhibition Is Effective Therapy for Aggressive B-Cell Lymphomas in Both Pre-Clinical and Clinical Studies of Disease.

PD-1 Is Elevated on the Peripheral Blood T Cell Subsets of Patients with Relapsed/Refractory Hodgkin Lymphoma Compared to Normal Volunteers

Post Transplant Lymphoproliferative Disorders: Prognostic Features and Rituximab Impact In a 120 Case Single Institution Series

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only